Section Arrow
IONS.NASDAQ
- Ionis Pharmaceuticals
Quotes are at least 15-min delayed:2025/06/10 00:35 EDT
Last
 36.76
+1.47 (+4.17%)
Day High 
36.95 
Prev. Close
35.29 
1-M High
35.88 
Volume 
2.03M 
Bid
35.29
Ask
37.75
Day Low
35.49 
Open
35.89 
1-M Low
31.66 
Market Cap 
5.62B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 34.02 
20-SMA 33.65 
50-SMA 31.18 
52-W High 52.34 
52-W Low 23.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.99/-2.67
Enterprise Value
7.02B
Balance Sheet
Book Value Per Share
2.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
810.46M
Operating Revenue Per Share
3.86
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0762+0.0263+52.71%-- 
CTXRCitius Pharmaceuticals Inc1.37+0.519+60.99%-- 
RXRXRecursion Pharmaceuticals5.37-0.12-2.19%-- 
SNPXSynaptogenix3.48+1.07+44.40%2.76PE
CARMCarisma Therapeutics0.2268+0.0329+16.97%-- 
Quotes are at least 15-min delayed:2025/06/10 00:35 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.